MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor

Tuesday, September 29, 2026Annabel Kartal AllenView original

MSD's bet on targeting RAS comes amid the industry buzz around the approval of Revolution's OS-doubling pancreatic cancer drug, Rasonque.

Read the full article on the original site.